Financials data is unavailable for this security.
View more
Year on year Oxford Biomedica PLC 's revenues fell -36.04% from 139.99m to 89.54m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 39.16m to a larger loss of 157.49m.
| Gross margin | 44.37% |
|---|---|
| Net profit margin | -205.68% |
| Operating margin | -205.69% |
| Return on assets | -51.69% |
|---|---|
| Return on equity | -113.03% |
| Return on investment | -64.26% |
More ▼
Cash flow in GBPView more
In 2023, cash reserves at Oxford Biomedica PLC fell by 37.57m. However, Cash Flow from Investing totalled 2.81m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 28.52m for operations while cash used for financing totalled 12.70m.
| Cash flow per share | -1.61 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.7645 |
|---|---|
| Tangible book value per share | 0.4445 |
More ▼
Balance sheet in GBPView more
| Current ratio | 3.19 |
|---|---|
| Quick ratio | 2.90 |
| Total debt/total equity | 1.51 |
|---|---|
| Total debt/total capital | 0.5888 |
More ▼
Growth rates in GBP
Year on year, growth in earnings per share excluding extraordinary items dropped -295.01%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -293.04 |
